COMMUNICATION
Two Regions of the Ryanodine Receptor Involved in Coupling with L-Type Ca2+ Channels*

Junichi NakaiDagger , Naomi SekiguchiDagger , Thomas A. Rando§, Paul D. Allen, and Kurt G. Beamparallel **

From the Dagger  Department of Information Physiology, National Institute for Physiological Sciences, Myodaiji-cho, Okazaki, 444, Japan, the § Department of Veterans Affairs, Palo Alto, Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California 94305, the  Department of Anesthesiology, Brigham and Women's Hospital, Boston, Massachusetts 02115, and the parallel  Department of Anatomy and Neurobiology, College of Veterinary Medicine and Biomedical Sciences, Colorado State University, Fort Collins, Colorado 80523-1670

    ABSTRACT
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Ryanodine receptors (RyRs) are present in the endoplasmic reticulum of virtually every cell type and serve critical roles, including excitation-contraction (EC) coupling in muscle cells. In skeletal muscle the primary control of RyR-1 (the predominant skeletal RyR isoform) occurs via an interaction with plasmalemmal dihydropyridine receptors (DHPRs), which function as both voltage sensors for EC coupling and as L-type Ca2+ channels (Rios, E., and Brum, G. (1987) Nature 325, 717-720). In addition to "receiving" the EC coupling signal from the DHPR, RyR-1 also "transmits" a retrograde signal that enhances the Ca2+ channel activity of the DHPR (Nakai, J., Dirksen, R. T., Nguyen, H. T., Pessah, I. N., Beam, K. G., and Allen, P. D. (1996) Nature 380, 72-76). A similar kind of retrograde signaling (from RyRs to L-type Ca2+ channels) has also been reported in neurons (Chavis, P., Fagni, L., Lansman, J. B., and Bockaert, J. (1996) Nature 382, 719-722). To investigate the molecular mechanism of reciprocal signaling, we constructed cDNAs encoding chimeras of RyR-1 and RyR-2 (the predominant cardiac RyR isoform) and expressed them in dyspedic myotubes, which lack an endogenous RyR-1. We found that a chimera that contained residues 1,635-2,636 of RyR-1 both mediated skeletal-type EC coupling and enhanced Ca2+ channel function, whereas a chimera containing adjacent RyR-1 residues (2,659-3,720) was only able to enhance Ca2+ channel function. These results demonstrate that two distinct regions are involved in the reciprocal interactions of RyR-1 with the skeletal DHPR.

    INTRODUCTION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Dihydropyridine receptors (DHPRs)1 and ryanodine receptors (RyRs) are essential for excitation-contraction (EC) coupling in skeletal muscle (1, 4-6). The DHPRs represent voltage-sensing elements in the plasmalemma (1), and the RyRs function as Ca2+ release channels in the sarcoplasmic reticulum (7-9). In response to depolarization, the DHPRs undergo conformational changes that produce membrane-bound charge movements (10). As one consequence of these conformational changes, a signal is transmitted to the RyRs, causing them to release Ca2+ from the sarcoplasmic reticulum. These conformational changes also control a slowly activating L-type Ca2+ current, which mediates the entry of extracellular Ca2+ across the plasmalemma. However, the slow L-type Ca2+ current is not important for skeletal muscle-type EC coupling because this coupling persists under conditions that prevent the entry of extracellular Ca2+ (11). The use of dysgenic myotubes (12), which lack the endogenous alpha 1 subunit of the skeletal DHPR (alpha 1S), together with expression of cDNAs encoding chimeric combinations of alpha 1S and alpha 1C (the cardiac isoform of the DHPR alpha 1 subunit), has revealed (13) that the loop linking homology repeats II and III is critical for transmitting the orthograde, EC coupling signal from the skeletal DHPR to RyR-1, the predominant skeletal isoform of the RyR.

Recently, cultured myotubes from dyspedic mice (6), which lack a functional RyR-1 gene, have provided a skeletal muscle system that makes it possible to express and functionally analyze cDNAs encoding RyRs. Results with dyspedic myotubes indicate that in addition to the "orthograde" (EC coupling) signal from DHPRs to RyRs in skeletal muscle, there also seems to be a "retrograde" signal from RyRs to DHPRs (2). Specifically, DHPRs appear to be present in the plasmalemma of dyspedic myotubes and able to undergo the voltage-driven conformational changes producing charge movement; however, the magnitude of slow L-type Ca2+ current is decreased in relationship to that of charge movement, indicating that the probability of channel opening is reduced and/or the channels open to less than the full conductance level. Expression in dyspedic myotubes of cDNA encoding RyR-1 causes the magnitude of the L-type Ca2+ current to return toward normal and also restores skeletal-type EC coupling. Expression in dyspedic myotubes of cDNA encoding RyR-2, the predominant cardiac RyR, fails to restore either orthograde signaling (skeletal-type EC coupling) or retrograde signaling (increased density of L-type Ca2+ current) (14).

To identify regions of RyR-1 important for reciprocal interactions with the skeletal DHPR, we have expressed cDNAs encoding chimeras of RyR-1 and RyR-2. We find that two distinct regions of RyR-1 appear to be important for reciprocal interactions with the DHPR.

    EXPERIMENTAL PROCEDURES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Construction of RyR cDNAs-- Because the RyR-1 plasmid (pRyR/Hygro) used in our previous experiments (2) lacked convenient restriction sites at the ends of the cDNA insert, we constructed a new RyR-1 plasmid (pCIneoRyR-1) as follows. MluI and XbaI sites were created before the Kozak initiation sequence (GCCGCC) and after the translation termination codon (15,112-15,114) of pRyR/Hygro, respectively, by means of polymerase chain reaction (PCR). The MluI-SalI (PCR-547) fragment amplified from pRyR/Hygro, the SalI-ClaI (547-14,313) fragment from pRyR/Hygro, and the ClaI-XbaI (14,313-PCR) fragment amplified from pRyR/Hygro were ligated to the MluI/XbaI sites of pCIneo (Promega) to yield pCIneoRyR-1. Because pRyR/Hygro and pCIneoRyR-1 behaved similarly, data from both clones are illustrated. The construction of pCIneoRyR-2 was described previously (14). Chimeric plasmids included the following sequences (PL designates the polylinker, and an asterisk designates a restriction site introduced by means of PCR). pCIneoR1: MluI-NdeI (PL-Sk 11,173) from pCIneoRyR-1 and NdeI-MluI (Ca 11,071-PL) from pCIneoRyR-2; pCIneoR2: MluI-BamHI (PL-Sk 4,894) from pCIneoRyR-1 and BamHI-MluI (Ca 4,867-PL) from pCIneoRyR-2; pCIneoR4: BamHI-NdeI (Sk 4, 894-11,173) from pCIneoRyR-1 and NdeI-BamHI (Ca 11,071-4,867) from pCIneoRyR-2; pCIneoR6: EcoRI-NdeI (Sk 2, 396-11,173) from pCIneoRyR-1 and NdeI-EcoRI (Ca 11,071-2,429*) from pCIneoRyR-2; pCIneoR9: AflII-NdeI (Sk 7,922*-11, 173) from pCIneoRyR-1 and NdeI-AflII (Ca 11,071-7,820) from pCIneoRyR-2; pCIneoR10: BamHI-AflII (Sk 4,894-7,922*) from pCIneoRyR-1 and AflII-BamHI (Ca 7,820-4,867) from pCIneoRyR-2. PCR was used to create EcoRI (Ca 2,429) and AflII (Sk 7,922) sites (by the mutations G2430A and C7923T, respectively) without altering the amino acid code. All fragments amplified by PCR were sequenced.

Functional Analysis-- The procedures for primary culture of dyspedic myotubes and for nuclear injection of plasmid DNA were as described previously (2, 5, 15). RyR cDNAs (0.5 µg/µl except 0.1-0.5 µg/µl for pCIneoRyR-2) were coinjected with CD8 cDNA (0.1 µg/µl) (16). Cells expressing the injected plasmids were identified on the basis of contraction and/or binding of CD8 antibody-coated beads (16) and were analyzed 1-4 days after plasmid injection.

Ca2+ currents were measured with the whole cell patch clamp technique (2). In some instances, a 5-min exposure of cells to 0.1 mM BAPTA-AM (at room temperature) was used to abolish spontaneous contractions. The patch pipette contained (mM) 140 cesium aspartate, 5 MgCl2, 10 Cs2EGTA (20 nM free Ca2+), 5 Na2ATP, and 10 HEPES (pH 7.4 with CsOH) with or without 0.2 or 0.4 pentapotassium Fluo-3. The bath solution contained (mM) 145 tetraethylammonium+, 165 Cl-, 10 HEPES (pH 7.4 with CsOH), 0.003 tetrodotoxin, and 10 Ca2+. The voltage clamp command sequence consisted of stepping from the holding potential (-80 mV) to -30 mV for 1 s, to -50 mV for 25-30 ms, to the test potential for 200 ms, to -50 mV for 25-30 ms, and then back to the holding potential.

To analyze intracellular Ca2+ transients in response to electrical stimulation, myotubes were loaded with Fluo-3 AM, and fluorescence changes (in arbitrary units) were measured as described previously (17). The cells were bathed in either normal rodent Ringer containing (mM) 145 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 HEPES (pH 7.4 with NaOH), or in Ca2+-free Ringer (made by equimolar substitution of Mg2+ for Ca2+ in the normal rodent Ringer). Cells were stimulated with a 10-ms pulse applied via an extracellular pipette (5, 17). Temperature was 20-22 °C.

    RESULTS
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Based on both hydropathy profile (6, 18-22) and comparison of sequence with the inositol 1,4,5-trisphosphate receptor, the other intracellular Ca2+ release channel (23), RyRs are predicted to have two main regions: a cytoplasmic "foot" structure representing the amino-terminal nine-tenths of the protein and a channel region comprising the carboxyl-terminal tenth. Additional support for this general architecture is provided by the recent observation that even after removal of the majority of the amino-terminal (~80%), the remaining carboxyl-terminal portion of RyR-1 is still able to form functional Ca2+ release channels (24). Because the foot bridges the gap between the sarcoplasmic reticulum and the sarcolemma (25), it would seem to be the part of the RyR most likely to participate in reciprocal interactions with the DHPR. To identify regions of RyR-1 (18, 19) critical for these reciprocal interactions, we constructed six cDNAs encoding chimeric RyRs in which a varying portion of the foot region of RyR-2 (20, 21) was replaced with the corresponding portion of RyR-1 (Fig. 1). The chimeric RyRs were expressed in myotubes obtained from dyspedic mice, which lack an intact RyR-1 gene (2). This approach is based on previous work with dyspedic myotubes, which demonstrated that (a) expression of RyR-1 both restored skeletal-type EC coupling (i.e. not requiring entry of extracellular Ca2+) and enhanced the Ca2+ channel activity of the DHPR (2) and (b) expression of RyR-2 neither restored skeletal-type EC coupling nor enhanced L-type Ca2+ channel activity (14). The RyR expression plasmids were co-injected with a plasmid encoding CD8 T-cell antigen into nuclei of dyspedic myotubes. Myotubes selected for analysis displayed spontaneous and/or electrically evoked contractions together with decoration by CD8 antibody-coated beads (16), which had been added to the bathing medium.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 1.   Schematic representation of the RyR chimeras, with regions having skeletal (RyR-1) sequence represented by thick lines and regions having cardiac (RyR-2) sequence represented by thin lines. The labels D1, D2, and D3 indicate three regions of RyR-1 highly divergent from RyR-2 (28). The + and - symbols indicate whether or not the expression of the construct enhanced ICa2+ or restored skeletal-type EC coupling. Amino acid composition of the chimeras is given below, with Sk and Ca indicating RyR-1 and RyR-2, respectively; when RyR-1 and RyR-2 sequence are identical in the region flanking a joining site, amino acid numbers are given as if the entire flanking region were of RyR-1 sequence. R1: Sk(1-3,720), Ca(3,687-4,968); R2: Sk(1-1,631), Ca(1,623-4,968); R4: Ca(1-1,625), Sk(1,635-3,720), Ca(3,687-4,968); R6: Ca(1-822), Sk(812-3,720), Ca(3,687-4,968); R9: Ca(1-2,624), Sk(2,659-3,720), Ca(3,687-4,968); R10: Ca(1-1,625), Sk(1,635-2,636), Ca(2,603-4,968).

Fig. 2 illustrates whole cell Ca2+ currents and Ca2+ transients recorded from myotubes expressing wild-type or chimeric RyRs. In order to minimize the amount of exogenous Ca2+ buffering, the Ca2+ transients were measured in intact myotubes loaded with Fluo-3 AM. Some of the chimeric RyRs caused spontaneous oscillatory contractions like those previously described for RyR-2 (14, 26). Therefore, BAPTA-AM was used in some experiments to suppress the contractions before measurement of Ca2+ currents (see legend to Fig. 2). Control experiments on normal myotubes demonstrated that the Ca2+ current density was slightly lower in BAPTA-AM-treated cells (11.3 ± 2.7 pA/pF, n = 10) than in nontreated cells (16.8 ± 4.1 pA/pF, n = 15). As reported previously, dyspedic myotubes had a small Ca2+ current density (2, 27) and lacked EC coupling (2, 6), both of which were restored toward normal after expression of RyR-1 (Fig. 2) (2). The restored EC coupling was skeletal-type because the depolarization-evoked Ca2+ transient was observed even in the absence of extracellular Ca2+. Also as reported previously, expression of RyR-2 restored neither L-type Ca2+ current (14) nor depolarization-induced Ca2+ release (even when external Ca2+ was present) (14, 26). The chimera R1, in which the majority of the amino-terminal portion of RyR-2 was replaced with RyR-1 sequence (1-3, 720), restored both Ca2+ current density and skeletal-type EC coupling. Therefore, the foot portion of RyR-1 is important for reciprocal interactions with the skeletal DHPR.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 2.   Representative Ca2+ currents and Ca2+ transients of the RyR chimeras expressed in dyspedic myotubes. Ca2+ currents were recorded from myotubes depolarized from -80 to +30 mV for 200 ms preceded by a 1-s prepulse to -30 mV to inactivate T-type Ca2+ current. Ca2+ transients were measured using Fluo-3 AM. Myotubes were electrically stimulated (displayed by vertical lines) with and without extracellular Ca2+. Ca2+ current densities (mean ± S.D. in pA/pF; numbers of cells given in parentheses): Normal, 11.3 ± 2.7 (10); Dyspedic, 0.98 ± 0.65 (20); RyR-1, 6.2 ± 2.5 (12); RyR-2, 0.17 ± 0.1 (10); R1, 8.9 ± 3.7 (9); R2,0.21 ± 0.27 (10); R4, 5.3 ± 1.9 (8); R6, 7.5 ± 3.6 (14); R9, 5.1 ± 2.2 (10); R10, 3.8 ± 1.7 (9). Data for dyspedic and RyR-1 were from Ref. 2; data for RyR-2 were from Ref. 14; BAPTA-AM treatment was used for normal myotubes, R2, and R9.

To localize more precisely the RyR regions critical for reciprocal interaction with the skeletal DHPR, we next examined chimeras that contained segments of RyR-1 sequence smaller than in R1. The chimera R2, which contained the RyR-1 sequence (1-1,631) corresponding only to the amino-terminal half of that in R1, restored neither Ca2+ current nor EC coupling. Despite being unable to interact reciprocally with the DHPR, R2 did encode a functional protein because myotubes expressing R2 cDNA displayed spontaneous, oscillatory contractions and could release Ca2+ in response to application of 0.1 mM caffeine (data not shown). Because R1 (RyR-1: 1-3, 720) could reciprocally interact with the skeletal DHPR but R2 (RyR-1: 1-1, 631) could not, we next examined chimeras R6 (RyR-1: 812-3,720), R4 (RyR-1: 1,635-3, 720), and R9 (RyR-1: 2,659-3,720), in which successively longer portions of the RyR-1 sequence at the amino terminus of R1 were replaced with RyR-2 sequence. The R6 and R4 chimeras were able both to increase Ca2+ current density and to restore skeletal-type EC coupling. Chimera R9 increased Ca2+ current density and restored a depolarization-induced Ca2+ transient that was present only when there was extracellular Ca2+. It is unlikely that Ca2+ entering via the enhanced, slow L-type Ca2+ current was by itself sufficient to produce this Ca2+ transient because even a large, rapidly activating Ca2+ current (resulting from heterologously expressed L-channels) produces only a small change in myoplasmic Ca2+ in dyspedic myotubes (14). Thus, R9 appears capable of supporting Ca2+-induced Ca2+ release but cannot mediate skeletal-type EC coupling. Because R4 (RyR-1: 1,635-3,720) supported skeletal-type coupling and R9 (RyR-1: 2,659-3,720) did not, we next examined R10 (RyR-1: 1,635-2,636). R10 both supported skeletal-type coupling and increased the density of L-type Ca2+ current (Fig. 2).

    DISCUSSION
Top
Abstract
Introduction
Procedures
Results
Discussion
References

Three regions, which have been designated D1, D2, and D3 (28), are particularly divergent between RyR-1 (18, 19) and RyR-2 (20, 21). Yamazawa et al. reported that deletion of D2 (RyR-1: 1,342-1,403) abolishes the ability of RyR-1 to mediate skeletal-type EC coupling, although EC coupling is preserved when the sequence of the D2 region is converted to RyR-2 sequence (29). Our data indicate that neither D2 nor D1 (RyR-1: 4,254-4,631) is important for the difference between RyR-1 and RyR-2 in mediating skeletal-type EC coupling and enhanced Ca2+ channel activity of the DHPR (Fig. 1). However, the D3 region (RyR-1: 1,872-1,923), which contains a cluster of acidic residues not present in RyR-2, could have specific importance for the ability of RyR-1 to mediate skeletal-type EC coupling because the R10 chimera includes the D3 region.

Fig. 3 is a schematic model of interactions between the DHPR and RyR in skeletal muscle. The skeletal DHPR is an L-type Ca2+ channel with voltage-sensing elements that have been adapted to control the gating of the slow L-type Ca2+ current and also to initiate EC coupling by triggering the opening of the Ca2+ release channel (i.e. RyR-1). Previous work has shown that the putative, intracellular loop connecting repeats II and III of the DHPR is critical for skeletal-type EC coupling (13, 30-32). The demonstration here that chimera R10 restores skeletal-type EC coupling suggests the possibility that the II-III loop triggers Ca2+ release by means of contact with RyR-1 in a region delimited by amino acids 1,635-2,636. Because L-type Ca2+ current density was increased by both R10 and R9, some of the residues between 1,635 and 2,636, as well as residues between 2,659 and 3,720, may represent sites of contact for retrograde signaling whereby RyR-1 enhances Ca2+ channel activity of the DHPR (2). Interestingly, R10 and R9 are contained within two calpain digestion fragments of RyR-1 (1,401-2,843 and 2,844-4,685), which appear to be linked by an intrasubunit disulfide bridge (33). No matter what the actual folding structure of RyRs, the demonstration that R9 enhances L-type Ca2+ channel activity without restoring skeletal-type EC coupling indicates that the structures of RyR-1 involved in retrograde (channel-enhancing) signaling are not identical to those involved in orthograde (EC coupling) signaling. Because RyR-1 is expressed in brain (22, 34-36), it will be important to determine whether the regions we have identified here are also involved in reciprocal signaling in neurons.


View larger version (49K):
[in this window]
[in a new window]
 
Fig. 3.   A schematic model of reciprocal coupling between the skeletal DHPR and RyR-1. For simplicity, the tetrameric structure of the RyR (37) is not represented. In response to depolarization of the transverse tubules (TT), voltage-sensing structures (VS) of the DHPR activate RyR-1 to release Ca2+ from the sarcoplasmic reticulum (SR). This interaction, which may involve a direct, physical interaction between the DHPR and RyR-1 (30-32), is indicated by the downward arrow. The DHPR also functions as an L-type Ca2+ channel. The coupling between the voltage-sensing structures and opening of the L-type Ca2+ channel is enhanced by an interaction with RyR-1 (indicated by the upward arrow) (2). The results described in this paper suggest that region I (amino acids 1,635-2,636) of RyR-1 receives the EC coupling signal, and both region I and region II (amino acids 2,659-3,720) participate in enhancement of L-type Ca2+ current.

    ACKNOWLEDGEMENTS

We thank Dr. N. Suda for helpful discussions and K. Lopez for technical help.

    FOOTNOTES

* This work was supported by grants from the Japan Ministry of Education, Science, Culture and Sports, from the Research for the Future Program (The Japan Society for the Promotion of Science) (to J. N.), from the American Academy of Neurology (to T. A. R.), and from the Muscular Dystrophy Association (to T. A. R. and P. D. A.) and by National Institutes of Health Grants AR44750 (to P. D. A. and K. G. B.) and NS24444 (to K. G. B.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

** To whom correspondence should be addressed. Tel.: 970-491-1566; Fax: 970-491-7907; E-mail: kbeam{at}lamar.colostate.edu.

1 The abbreviations used are: DHPR, dihydropyridine receptor; RyR, ryanodine receptor; EC, excitation-contraction; PCR, polymerase chain reaction; BAPTA-AM, 1,2-bis(o-aminophenoxy)ethane-N,N,N',N',-tetraacetic acid tetraacetoxymethyl ester; Fluo-3, 1-[2-amino-5-(2,7-dichloro6-hydroxy-3-oxo-3H-xanthen-9-yl)]-2-(2'-amino-5'-methylphenoxy)ethane-N,N,N',N'-tetraacetic acid pentaacetoxymethyl ester.

    REFERENCES
Top
Abstract
Introduction
Procedures
Results
Discussion
References

  1. Rios, E., and Brum, G. (1987) Nature 325, 717-720[CrossRef][Medline] [Order article via Infotrieve]
  2. Nakai, J., Dirksen, R. T., Nguyen, H. T., Pessah, I. N., Beam, K. G., and Allen, P. D. (1996) Nature 380, 72-76[CrossRef][Medline] [Order article via Infotrieve]
  3. Deleted in proof
  4. Beam, K. G., Knudson, C. M., and Powell, J. A. (1986) Nature 320, 168-170[Medline] [Order article via Infotrieve]
  5. Tanabe, T., Beam, K. G., Powell, J. A., and Numa, S. (1988) Nature 336, 134-139[CrossRef][Medline] [Order article via Infotrieve]
  6. Takeshima, H., Iino, M., Takekura, H., Nishi, M., Kuno, J., Minowa, O., Takano, H., and Noda, T. (1994) Nature 369, 556-559[CrossRef][Medline] [Order article via Infotrieve]
  7. Imagawa, T., Smith, J. S., Coronado, R., and Campbell, K. P. (1987) J. Biol. Chem. 262, 16636-16643[Abstract/Free Full Text]
  8. Lai, F. A., Erickson, H. P., Rousseau, E., Liu, Q.-Y., and Meissner, G. (1988) Nature 331, 315-319[CrossRef][Medline] [Order article via Infotrieve]
  9. Hymel, L., Inui, M., Fleischer, S., and Schindler, H. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 441-445[Abstract]
  10. Schneider, M. F., and Chandler, W. K. (1973) Nature 242, 244-246[Medline] [Order article via Infotrieve]
  11. Armstrong, C. M., Bezanilla, F. M., and Horowicz, P. (1972) Biochem. Biophys. Acta 267, 605-608[Medline] [Order article via Infotrieve]
  12. Gluecksohn-Waelsch, S. (1963) Science 142, 1269-1276[Medline] [Order article via Infotrieve]
  13. Tanabe, T., Beam, K. G., Adams, B. A., Niidome, T., and Numa, S. (1990) Nature 346, 567-569[CrossRef][Medline] [Order article via Infotrieve]
  14. Nakai, J., Ogura, T., Protasi, F., Franzini-Armstrong, C., Allen, P. D., and Beam, K. G. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 1019-1022[Abstract/Free Full Text]
  15. Rando, T. A., and Blau, H. M. (1994) J. Cell Biol. 125, 1275-1287[Abstract]
  16. Jurman, M. E., Boland, L. M., Liu, Y., and Yellen, G. (1994) BioTechniques 17, 876-881[Medline] [Order article via Infotrieve]
  17. García, J., and Beam, K. G. (1994) J. Gen. Physiol. 103, 107-123[Abstract]
  18. Takeshima, H., Nishimura, N., Matsumoto, T., Ishida, H., Kangawa, K., Minamino, N., Matsuo, H., Ueda, M., Hanaoka, M., Hirose, T., and Numa, S. (1989) Nature 339, 439-445[CrossRef][Medline] [Order article via Infotrieve]
  19. Zorzato, F., Fujii, J., Otsu, K., Green, N. M., Lai, F. A., Meissner, G., and MacLennan, D. H. (1990) J. Biol. Chem. 265, 2244-2256[Abstract/Free Full Text]
  20. Nakai, J., Imagawa, T., Hakamata, Y., Shigekawa, M., Takeshima, H., and Numa, S. (1990) FEBS Lett. 271, 169-177[CrossRef][Medline] [Order article via Infotrieve]
  21. Otsu, K., Willard, H. F., Khanna, V. K., Zorzato, F., Green, N. M., and MacLennan, D. H. (1990) J. Biol. Chem. 265, 13472-13483[Abstract/Free Full Text]
  22. Hakamata, Y., Nakai, J., Takeshima, H., and Imoto, K. (1992) FEBS Lett. 312, 229-235[CrossRef][Medline] [Order article via Infotrieve]
  23. Furuichi, T., Yoshikawa, S., Miyawaki, A., Wada, K., Maeda, N., and Mikoshiba, K. (1989) Nature 342, 32-38[CrossRef][Medline] [Order article via Infotrieve]
  24. Bhat, M. B., Zhao, J., Takeshima, H., and Ma, J. (1997) Biophys. J. 73, 1329-1336[Abstract]
  25. Takekura, H., Nishi, M., Noda, T., Takeshima, H., and Franzini-Armstrong, C. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3381-3385[Abstract]
  26. Yamazawa, T., Takeshima, H., Sakurai, T., Endo, M., and Iino, M. (1996) EMBO J. 15, 6172-6177[Abstract]
  27. Fleig, A., Takeshima, H., and Penner, R. (1996) J. Physiol. 496, 339-345[Abstract]
  28. Sorrentino, V., and Volpe, P. (1993) Trends Pharmacol. Sci. 14, 98-103[CrossRef][Medline] [Order article via Infotrieve]
  29. Yamazawa, T., Takeshima, H., Shimuta, M., and Iino, M. (1997) J. Biol. Chem. 272, 8161-8164[Abstract/Free Full Text]
  30. Lu, X., Xu, L., and Meissner, G. (1994) J. Biol. Chem. 269, 6511-6516[Abstract/Free Full Text]
  31. Lu, X., Xu, L., and Meissner, G. (1995) J. Biol. Chem. 270, 18459-18464[Abstract/Free Full Text]
  32. El-Hayek, R., Antoniu, B., Wang, J., Hamilton, S. L., and Ikemoto, N. (1995) J. Biol. Chem. 270, 22116-22118[Abstract/Free Full Text]
  33. Wu, Y., Aghdasi, B., Dou, S. J., Zhang, J. Z., Liu, S. Q., and Hamilton, S. L. (1997) J. Biol. Chem. 272, 25051-25061[Abstract/Free Full Text]
  34. Kuwajima, G., Futatsugi, A., Niinobe, M., Nakanishi, S., and Mikoshiba, K. (1992) Neuron 9, 1133-1142[Medline] [Order article via Infotrieve]
  35. Furuichi, T., Furutama, D., Hakamata, Y., Nakai, J., Takeshima, H., and Mikoshiba, K. (1994) J. Neurosci. 14, 4794-4805[Abstract]
  36. Giannini, G., Conti, A., Mammarella, S., Scrobogna, M., and Sorrentino, V. (1995) J. Cell Biol. 128, 893-904[Abstract]
  37. Inui, M., Saito, A., and Fleischer, S. (1987) J. Biol. Chem. 262, 1740-1747[Abstract/Free Full Text]


Copyright © 1998 by The American Society for Biochemistry and Molecular Biology, Inc.